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Abstract
Purpose Benign breast disease (BBD) is an important
risk factor for subsequent breast cancer. However, it is
unclear whether breast cancer risk is higher in cases of
atypical ductal hyperplasia (ADH) than atypical lobular
hyperplasia (ALH). Furthermore, it is unclear whether
family history increases risk in women with various sub-
types of BBD.
Methods We searched the electronic database of PubMed
for case–control studies about the subsequent breast cancer
risk of BBD, and a meta-analysis was conducted.
Results Of ten inclusive studies, nine were eligible for
subsequent breast cancer risk of histological subtype,
including 2,340 cases and 4,422 controls, and four were
eligible for investigating the inﬂuence of family history on
subtypes of BBD, including 1,377 cases and 2,630 controls.
Relative to non-proliferative disease (NP), all subtypes of
BBD increased subsequent risk, and risk for women with
ALH (OR = 5.14, 95% CI 3.52–7.52) may be higher than
for women with ADH (OR = 2.93, 95% CI 2.16–3.97).
Compared to women without family history and prolifer-
ative disease, women with a ﬁrst-degree family history and
atypical hyperplasia (AH) were at highest risk (OR = 4.87,
95% CI 2.89–8.20). Relative to women without family
history, women with a ﬁrst-degree family history had an
increased breast cancer risk in different histological
subtypes of BBD except for AH (OR = 1.39, 95% CI
0.82–2.37).
Conclusion This meta-analysis strongly suggested that
women with AH, especially for ALH and AH combined
with a ﬁrst-degree family history, were at high risk, for
whom risk-reduction options should be considered.
Keywords Benign breast disease  Family history 
Breast cancer risk  Meta-analysis
Introduction
With the increased use of mammography, more and more
women are diagnosed with various subtypes of benign
breast disease (BBD) (Kuzma 1969; Kalache 1981). Since
BBD is a very important risk factor for subsequent breast
cancer, it is necessary to estimate the risk of breast cancer
for speciﬁc histological categories. BBD is usually subdi-
vided into non-proliferative disease (NP), proliferative
disease without atypia (PDWA), and atypical hyperplasia
(AH) (Dupont and Page 1985; Gail et al. 1989; Fitzgibbons
et al. 1998). AH is usually categorized into atypical ductal
hyperplasia (ADH) and atypical lobular hyperplasia
(ALH). Women with PDWA had a 1.5–2 times higher risk
of breast cancer compared to women without BBD, while
an approximately four-fold increased risk of breast cancer
for AH was corroborated by previous studies (Dupont and
Page 1985; Hartmann et al. 2005; Page et al. 1985; Dupont
et al. 1993; London et al. 1992). However, it is unclear
whether breast cancer risk is higher in cases of ADH versus
ALH (Degnim et al. 2007; Kabat et al. 2010; Collins et al.
2007). Some studies (Collins et al. 2007; Kabat et al. 2010)
suggested that ALH was associated with a higher risk than
ADH, so that more active management should be
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DOI 10.1007/s00432-011-0979-zconsidered for women with ALH. However, breast cancer
risk was similar for ADH and ALH in a Mayo cohort study
(Degnim et al. 2007). Family history is also a key com-
ponent of breast cancer risk assessment (Ready and Arun
2010). Women with a positive family history and a special
subtype of BBD may have increased risk. However, it is
still unclear whether a positive family history increases
breast cancer risk in women with all subtypes of BBD
(Dupont and Page 1985; London et al. 1992; Carter et al.
1988; Degnim et al. 2007).
According to American Society of Clinical Oncology
(ASCO) clinical practice guideline, women at risk should
be considered with optimal management, including
increased screening, chemoprevention, and prophylactic
surgery. For women at average risk, screening mammog-
raphy should be performed every 1–2 years, while for
women at high risk, screening mammography should be
performed every 6–12 months (Grifﬁn and Pearlman
2010). Although AH and a positive family history were
associated with increased breast cancer risk, the majority of
women with proliferative disease (PD) and/or a positive
family history would not develop breast cancer. Thus, it is
necessary to identify individuals with high breast cancer
risk. The purpose of this meta-analysis was to investigate
the subtype of BBD with high breast cancer risk and the
inﬂuence of a positive family history on various subtypes
of BBD.
Methods
Search strategy
Meta-analysis was performed as described previously (Liu
et al. 2010). Relevant studies were selected by searching
PubMed (updated on September 2010), using the following
terms: case–control, breast cancer or breast neoplasm, and
benign breast disease or proliferative disease or atypia.
Two reviewers (Zhou WB and Xue DQ) independently
evaluated titles and abstracts of the identiﬁed papers.
References in identiﬁed articles and previous reviews were
also reviewed for possible inclusion. Only those published
studies in English language with full text articles were
included in this meta-analysis. Studies were included if
they met the following criteria: (1) the diagnosis of BBD
and breast cancer was conﬁrmed histopathologically; (2)
BBD that was subdivided into NP, PDWA, and AH by
biopsy; (3) a case–control study examining the association
between BBD and breast cancer risk; and (4) sufﬁcient
published data for estimating an odds ratio (OR) with 95%
conﬁdence interval (CI). For overlapping studies, only the
one with the largest sample numbers was selected.
Data extraction
Information was carefully extracted from all the eligible
studies independently by two reviewers (Zhou WB and
Xue DQ). The following variables were extracted from
each study if available: ﬁrst author’s name, publication
year, country of origin, study design, numbers of cases and
controls, numbers of cases and controls in different sub-
types of BBD, and numbers of cases and controls in
different subtypes of BBD on family history. After dis-
agreement was resolved by discussion, all the data were
reached consensus.
Statistical analysis
Crude odds ratios with 95% conﬁdence interval were used
to assess the association between the subtypes of biopsy-
proved BBD and subsequent breast cancer risk. Otherwise,
the association between different subtypes of BBD on
Table 1 Characteristics of case–control studies about histologic stratiﬁcation included in the meta-analysis
Author Population Year Design Cases Controls
Total NP PDWA AH (ADH/ALH) Total NP PDWA AH (ADH/ALH)
Bianchi Italy (CSPO) 1992 Nested case–control 62 45 6 11 315 277 31 7
McDivitt USA (CSHS) 1992 Case–control 417 227 124 66 248 154 68 26
Stark USA (Mayo) 2000 Nested case–control 137 98 34 5 (5/0) 156 115 37 4 (4/0)
Byrne USA (BCDDP) 2001 Nested case–control 318 62 198 58 358 94 223 41
Shaaban British 2002 Case–control 117 62 38 17 (7/10) 345 248 79 18 (11/7)
Collins USA (Nurse) 2007 Nested case–control 395 99 200 96 (45/36) 1,610 611 839 160 (103/42)
Boulos USA (NBC) 2008 Nested case–control 77 24 39 14 152 56 58 38
Worsham USA (HFHS) 2009 Nested case–control 202 48 125 29 (22/10) 614 234 349 31 (22/9)
Kabat Ca, USA, UK 2010 Nested case–control 615 190 393 32 (13/16) 624 250 362 12 (6/5)
NP non-proliferative, PDWA proliferative disease without atypia, AH atypical hyperplasia, ADH atypical ductal hyperplasia, ALH atypical
lobular hyperplasia
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123family history and subsequent breast cancer risk was also
evaluated. The between-study heterogeneity was tested
with Q statistics (Lau et al. 1997). If P\0.10, the
between-study heterogeneity was considered to be signiﬁ-
cant. When between-study heterogeneity was absent, the
ﬁxed-effects model (the Mantel–Haenszel method) (Mantel
and Haenszel 1959) was used to calculate the pooled OR.
Otherwise, a random-effects model (the DerSimonian and
Laird method) (DerSimonian and Laird 1986) was selected.
Publication bias was investigated by funnel plot, in which
the standard error of log (OR) of each study was plotted
against its log (OR). Funnel plot asymmetry was assessed
by the method of Egger’s linear regression test, a linear
regression approach to measure funnel plot asymmetry on
the natural logarithm scale of the OR. The signiﬁcance of
the intercept was determined by the t test as suggested by
Egger, and a P value less than 0.05 was considered sig-
niﬁcant (Egger et al. 1997). All analyses were performed
using the software Stata version 11.0 (Stata Corporation,
College Station, TX, USA).
Results
Eligible studies
Ten case–control studies were included in this meta-
analysis. Of the ten studies, eight were nested within large
cohort studies (Table 1). As shown in Table 1, compared to
NP,nine studies (Kabat etal.2010; Stark etal.2000;Boulos
et al. 2008; McDivitt et al. 1992; Shaaban et al. 2002;
Worsham et al. 2009; Collins et al. 2007; Byrne et al. 2001;
Bianchi et al. 1992) were eligible for subsequent breast
cancer risk of PDWA and AH, including 2340 cases and
4422 controls. Of the nine studies, subsequent breast cancer
risk of ADH was reported in ﬁve studies (Stark et al. 2000;
Shaaban et al. 2002; Collins et al. 2007; Worsham et al.
2009; Kabat et al. 2010), and subsequent breast cancer risk
of ALH was reported in four studies (Shaaban et al. 2002;
Collins et al. 2007; Worsham et al. 2009; Kabat et al. 2010).
AsshowninTable 2,fourstudies(Kabatetal.2010;Dupont
et al. 1993; McDivitt et al. 1992; Collins et al. 2006) were
eligible for investigating the interplay between BBD (NP
and PD) and a ﬁrst-degree family history of breast cancer,
including1,377casesand2,630controls.Ofthefourstudies,
three studies (Dupont et al. 1993; McDivitt et al. 1992;
Collins et al. 2006) reported the interplay between the sub-
types of PD and a ﬁrst-degree family history.
Meta-analysis
Table 3 showed the main results of this meta-analysis.
Relative to NP, the OR for PDWA was 1.44 (95% CI
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1231.28–1.63, P = 0.80 for heterogeneity); while two studies
published in 1992 were excluded, the OR for PDWA was
1.48 (95% CI 1.30–1.69, P = 0.73 for heterogeneity); for
AH, OR was 2.81 (95% CI 1.91–4.12, P\0.01 for het-
erogeneity); while two studies published in 1992 were
excluded, the OR for AH was 2.72 (95% CI 1.83-4.04,
P = 0.01 for heterogeneity); for ADH, OR was 2.93 (95%
CI 2.16-3.97, P = 0.48 for heterogeneity) (Fig. 1); for
ALH, OR was 5.14 (95% CI 3.52–7.52, P = 0.98 for
heterogeneity) (Fig. 2).
Family history was an independent risk factor in this
meta-analysis. When the women without a ﬁrst-degree
family history and PD were used as reference group,
women with a ﬁrst-degree family history and AH had a
highest risk (Table 3) (OR = 4.87, 95% CI 2.89–8.20,
P = 0.26 for heterogeneity).
When the women in different histological subtypes
without a ﬁrst-degree family history were used as reference
group, a ﬁrst-degree family history did not increase risk in
women with AH (OR = 1.39, 95% CI 0.82–2.37, P = 0.53
for heterogeneity). However, a ﬁrst-degree family history
increased risk in women with other histological subtypes.
Relative to women without family history, for NP, the OR
for women with family history was 1.64 (95% CI
1.21–2.22, P = 0.16 for heterogeneity) (Fig. 3); for PD,
the OR for women with family history was 1.35 (95% CI
Table 3 Summary ORs and
95% CI of subsequent breast
cancer risk
NP non-proliferative disease,
PD proliferative disease, PDWA
proliferative disease without
atypia, AH atypical hyperplasia,
ADH atypical ductal
hyperplasia, ALH atypical
lobular hyperplasia
* Estimates for random-effects
model
Modifying factor Histology Odds ratio 95% CI P value for
heterogeneity
Histology
NP 1.00 Reference
PDWA 1.44 1.28–1.63 0.80
AH 2.81 1.91–4.12 \0.01*
ADH 2.93 2.16–3.97 0.48
ALH 5.14 3.52–7.52 0.98
Family history
Absent NP 1.00 Reference
PD 1.67 1.41–1.97 0.57
PDWA 1.39 1.10–1.75 0.48
AH 3.10 2.27–4.25 0.11
Present NP 1.64 1.21–2.22 0.16
PD 2.30 1.80–2.94 0.20
PDWA 2.35 1.66–3.33 0.93
AH 4.87 2.89–8.20 0.26
Fig. 1 Forest plot for meta-
analysis of breast cancer risk
from BBD for women with
atypical ductal hyperplasia
compared to non-proliferative
disease. The width of the
horizontal line represents the
95% CI of the individual
studies, and the square
proportional represents the
weight of each study. The
diamond represents the pooled
OR and 95% CI
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1231.09–1.69, P = 0.22 for heterogeneity) (Fig. 4); and for
PDWA, the OR for women with family history was 1.61
(95% CI 1.17–2.22, P = 0.66 for heterogeneity).
Funnel plot and Egger’s test were performed to access
the publication bias of literatures. In overall studies, no
signiﬁcant publication bias (P[0.05) existed (data not
shown).
Discussion
The present meta-analysis was conducted to investigate the
subtype of BBD with high breast cancer risk and the
inﬂuence of a positive family history on various subtypes
of BBD. This study showed that all subtypes of BBD
increased the subsequent breast cancer risk, and ALH had a
highest risk. Furthermore, our results suggested that a ﬁrst-
degree family history increased risk in women with NP and
PD. Although compared to women without family history
and PD, women with a ﬁrst-degree family history and AH
had the highest risk; a ﬁrst-degree family history did not
increase risk in women with AH. Increased screening,
chemoprevention, and even prophylactic surgery should be
considered for women with ALH or women with a ﬁrst-
degree family history and AH.
Consistent with previous studies, our study showed that
PDWA had a slightly increased risk (OR = 1.44, 95% CI
1.28–1.63) of breast cancer, and AH had a substantially
Fig. 2 Forest plot for meta-
analysis of breast cancer risk
from BBD for women with
atypical lobular hyperplasia
compared to non-proliferative
disease. The width of the
horizontal line represents the
95% CI of the individual
studies, and the square
proportional represents the
weight of each study. The
diamond represents the pooled
OR and 95% CI
Fig. 3 Forest plot for meta-
analysis of breast cancer risk
from non-proliferative disease
for women with a ﬁrst-degree
family history compared to
women without family history.
The width of the horizontal line
represents the 95% CI of the
individual studies, and the
square proportional represents
the weight of each study. The
diamond represents the pooled
OR and 95% CI
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123increased risk (OR = 2.81, 95% CI 1.91–4.12). Worsham
et al. (2007) suggested that breast cancer risk from BBD for
women with ADH may be higher than for women with
ALH. However, the opposite results were reported in other
studies (Fitzgibbons et al. 1998; Kabat et al. 2010; Collins
et al. 2007). This meta-analysis suggested that breast can-
cer risk from BBD for women with ALH (OR = 5.14, 95%
CI 3.52–7.52) may be higher than for women with ADH
(OR = 2.93, 95% CI 2.16-3.97). Previous study (Hartmann
et al. 2005) showed that degree of family history was an
independent risk factor. The risk ratio of breast cancer for
NP women with a weak family history was 1.12, but no
signiﬁcant difference was observed. The women with a
ﬁrst-degree family history were included in this study for
investigating the interplay between BBD and family his-
tory of breast cancer, and the ﬁrst-degree family history
was a signiﬁcant risk factor for women with different
histological subtypes of BBD except for AH. The future
large study should be carried out to evaluate the breast
cancer risk for women with different degrees of family
history.
Recommendations for breast cancer screening and risk-
reduction options for women at average risk were different
from women at high risk (Grifﬁn and Pearlman 2010).
Routine mammography should be performed for women at
average risk, but no special risk-reduction management
should be done (Grifﬁn and Pearlman 2010; Meissner et al.
2011). However, increased screening, chemoprevention,
and prophylactic surgery should be considered for women
at high risk. This meta-analysis suggested that women with
AH, especially for ALH and AH combined with a ﬁrst-
degree family history, were at high risk, so that risk-
reduction options should be considered.
Several issues may affect the efﬁciency of speciﬁc
types of BBD with risk of breast cancer. First, the
reference group used to examine the subsequent breast
cancer risk among women with BBD was variant in dif-
ferent studies. The general population was used as refer-
ence group in some studies (Hartmann et al. 2005; Carter
et al. 1988; McDivitt et al. 1992; Degnim et al. 2007),
while NP was used in others (Dupont and Page 1985;
London et al. 1992; Marshall et al. 1997; Worsham et al.
2009; Jacobs et al. 1999). In this meta-analysis, NP was
used as reference group for calculation although data were
extracted from studies with different reference groups.
Therefore, this study gave a more precise estimation of
the risk from a large sample. Second, there was no
pathological review in some studies (Wang et al. 2004),
and the classiﬁcation of BBD was unequal in different
centers (King et al. 2000; Patterson et al. 2004). However,
the breast lesions included in this meta-analysis were
all biopsy-proved BBD and reviewed by experienced
pathologists.
On the other hand, some limitations still exist in this
meta-analysis. First, both very old and relatively new
studies were included in this study; the methodological
limitation of this analysis should be considered. Second, of
these ten studies, most subjects were Caucasians, including
some African-Americans, while no Asians were included.
Therefore, the conclusion in Asian populations was still
unclear. Third, the present results were based on unad-
justed ORs, and more precise estimation may be adjusted
by other potential covariates.
In conclusion, this meta-analysis strongly suggested that
women with AH, especially for ALH and AH combined
with a ﬁrst-degree family history, were at high risk. So
risk-reduction options should be considered for these
women. Further study with larger sample size is necessary
to get more precise estimation of breast cancer risk after
diagnosis of BBD.
Fig. 4 Forest plot for meta-
analysis of breast cancer risk
from proliferative disease for
women with a ﬁrst-degree
family history compared to
women without family history.
The width of the horizontal line
represents the 95% CI of the
individual studies, and the
square proportional represents
the weight of each study. The
diamond represents the pooled
OR and 95% CI
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